Oral contraceptives and risk of ovarian and breast cancers in
BRCA mutation carriers: a meta-analysis

J 2011

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis

CIBULA, David; Michal ZIKÁN; Ladislav DUŠEK a Ondřej MÁJEK

Základní údaje

Originální název

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis

Autoři

CIBULA, David; Michal ZIKÁN; Ladislav DUŠEK a Ondřej MÁJEK

Vydání

Expert Review of Anticancer Therapy, 2011, 1473-7140

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.652

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00053296

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1586/ERA.11.38

UT WoS

000294978600012

Klíčová slova anglicky

breast cancer; BRCA1; BRCA2; combined oral contraceptives; ovarian cancer

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 6. 2012 17:14, RNDr. Ondřej Májek, Ph.D.

Anotace

V originále

Prophylactic salpingo-oophorectomy is currently the only effective strategy available for decreasing ovarian cancer risk in BRCA1/2 mutation carriers. Significantly decreased risk of ovarian cancer associated with the use of combined oral contraceptives (COCs) was shown in the general population, which could be an alternative approach for those who do not accept risk-reducing surgery. Cohort, case–control and case–case studies published in English up to December 2009 reporting the association of ovarian or breast cancer risk with the use of COCs and presenting BRCA status were selected for meta-analysis. Meta-analysis of three case–control studies showed a significant risk reduction of ovarian cancer in BRCA1/2 mutation carriers who were associated with any past COC use and significant trend by duration of COC use (OR: 0.95; 95% CI: 0.93–0.97). No significant increase in breast cancer risk associated with COC use has been found in case–control studies in BRCA1 (OR: 1.08; p = 0.250), in BRCA2 (OR: 1.03; p = 0.788) mutation carriers or in case–case studies in BRCA1/2 carriers (OR: 0.80; p = 0.147). Significantly increased risk of breast cancer was only shown on a subset of cohort studies in BRCA1 mutation carriers (OR: 1.48; 95% CI: 1.14–1.92). In conclusion, meta-analysis confirmed significantly decreased ovarian cancer risk in BRCA1/2 mutation carriers associated with the use of COCs comparable to the relative extent shown in the general population. Data on the risk of breast cancer associated with COC use in BRCA mutation carriers are heterogeneous and results are inconsistent. COCs can be considered as an alternative strategy in the chemoprevention of ovarian cancer in BRCA1 mutation carriers who do not accept prophylactic salpingo-oophorectomy above the age of 30 years.

Citovat

CIBULA, David; Michal ZIKÁN; Ladislav DUŠEK a Ondřej MÁJEK. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Review of Anticancer Therapy. 2011, roč. 11, č. 8, s. 1197-1207. ISSN 1473-7140. Dostupné z: https://doi.org/10.1586/ERA.11.38.

@article{951839,
   author = {Cibula, David and Zikán, Michal and Dušek, Ladislav and Májek, Ondřej},
   article_number = {8},
   doi = {https://doi.org/10.1586/ERA.11.38},
   keywords = {breast cancer; BRCA1; BRCA2; combined oral contraceptives; ovarian cancer},
   language = {eng},
   issn = {1473-7140},
   journal = {Expert Review of Anticancer Therapy},
   title = {Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis},
   volume = {11},
   year = {2011}
}

TY  - JOUR
ID  - 951839
AU  - Cibula, David - Zikán, Michal - Dušek, Ladislav - Májek, Ondřej
PY  - 2011
TI  - Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis
JF  - Expert Review of Anticancer Therapy
VL  - 11
IS  - 8
SP  - 1197-1207
EP  - 1197-1207
SN  - 14737140
KW  - breast cancer
KW  - BRCA1
KW  - BRCA2
KW  - combined oral contraceptives
KW  - ovarian cancer
N2  - Prophylactic salpingo-oophorectomy is currently the only effective strategy available for decreasing ovarian cancer risk in BRCA1/2 mutation carriers. Significantly decreased risk of ovarian cancer associated with the use of combined oral contraceptives (COCs) was shown in the general population, which could be an alternative approach for those who do not accept risk-reducing surgery. Cohort, case–control and case–case studies published in English up to December 2009 reporting the association of ovarian or breast cancer risk with the use of COCs and presenting BRCA status were selected for meta-analysis. Meta-analysis of three case–control studies showed a significant risk reduction of ovarian cancer in BRCA1/2 mutation carriers who were associated with any past COC use and significant trend by duration of COC use (OR: 0.95; 95% CI: 0.93–0.97). No significant increase in breast cancer risk associated with COC use has been found in case–control studies in BRCA1 (OR: 1.08; p = 0.250), in BRCA2 (OR: 1.03; p = 0.788) mutation carriers or in case–case studies in BRCA1/2 carriers (OR: 0.80; p = 0.147). Significantly increased risk of breast cancer was only shown on a subset of cohort studies in BRCA1 mutation carriers (OR: 1.48; 95% CI: 1.14–1.92). In conclusion, meta-analysis confirmed significantly decreased ovarian cancer risk in BRCA1/2 mutation carriers associated with the use of COCs comparable to the relative extent shown in the general population. Data on the risk of breast cancer associated with COC use in BRCA mutation carriers are heterogeneous and results are inconsistent. COCs can be considered as an alternative strategy in the chemoprevention of ovarian cancer in BRCA1 mutation carriers who do not accept prophylactic salpingo-oophorectomy above the age of 30 years.
ER  -

CIBULA, David; Michal ZIKÁN; Ladislav DUŠEK a Ondřej MÁJEK. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. \textit{Expert Review of Anticancer Therapy}. 2011, roč.~11, č.~8, s.~1197-1207. ISSN~1473-7140. Dostupné z: https://doi.org/10.1586/ERA.11.38.

Přehled o publikaci